Thromb Haemost 2001; 85(06): 1025-1030
DOI: 10.1055/s-0037-1615958
Review Article
Schattauer GmbH

Increased Hepatic Fibrinogen Bβ-gene Transcription Is not enough to Increase Plasma Fibrinogen Levels

A Transgenic Mouse Study
F. Rezaee
1   Department of Vascular and Connective Tissue Research, Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
A. Maas
1   Department of Vascular and Connective Tissue Research, Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
J. H. Verheijen
1   Department of Vascular and Connective Tissue Research, Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
J. Koopman
2   Pharming, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 11 September 2000

Accepted after resubmission 16 January 2001

Publication Date:
12 December 2017 (online)

Summary

The fibrinogen Aα, Bβ, and γ polypeptides are encoded by three separate genes, which are arranged in the order γ-α-β. In order to study the biosynthesis of fibrinogen in vivo we generated a line of transgenic mice carrying extra copies of the fibrinogen β-gene. To clone the mouse fibrinogen Bβ-chain gene, a mouse 129 Sv/Ev genomic cosmid library was screened, using the mouse fibrinogen Aα-, Bγ-chain cDNA. A clone containing the complete fibrinogen Bβ-chain gene including approximately 11-kb of the natural promoter region was identified and subsequently microinjected into mice. Southern blot analysis identified a founder that carried additional copies of the fibrinogen Bβ-chain gene. Transgenic offspring of this founder were interbred and heterozygous and homozygous transgenic mice were obtained. Northern blot analysis demonstrated approximately a 3-fold increase in fibrinogen Bβ mRNA in heterozygous mice as compared to wild-type, whereas homozygous transgenic mice showed approximately a 9-fold increase. The levels of the Aα and γ mRNAs in transgenic homozygous mice were not changed as compared to those in wild-type mice. Fibrinogen levels in plasma were not significantly increased in transgenic mice as compared to wild-type mice.

These results indicate that: additional copies of the fibrinogen Bβ-chain gene lead to increased levels of the Bβ-chain mRNA in the liver; the increased levels of Bβ-chain mRNA in homozygous overexpression mice do not change the transcription levels of the two other fibrinogen mRNAs in vivo; the absence of an increased plasma fibrinogen level in the transgenic mice indicates that this level is not regulated solely by transcription of the Bβ-chain gene.

 
  • References

  • 1 Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i: 1050-4.
  • 2 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
  • 3 Meade TW, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
  • 4 Kannel WB, Wolf PA, Castelli WP, DíAgostino RBD. Fibrinogen and risk of cardiovascular disease. The Framingham Study. J Am Med Assoc 1987; 258: 1183-6.
  • 5 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
  • 6 Heinrich J, Balleisen L, Schulte H, Assman G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 144: 54-9.
  • 7 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
  • 8 Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction – the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80: 749-56.
  • 9 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279: 1477-82.
  • 10 Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haemat 1986; 15: 355-70.
  • 11 Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, Hiroki T, Arakawa K. Plasma fibrinogen levels an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-13.
  • 12 Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
  • 13 Folsom AR, Wu KK, Shahar E, Davis CE. Association of haemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-36.
  • 14 Doolittle RF. Fibrinogen and fibrin. Ann Rev Biochem 1984; 53: 195-229.
  • 15 Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann NY Acad Sci 1983; 408: 28-43.
  • 16 Blömback B, Blömback M. The molecular structure of fibrinogen. Ann NY Acad Sci 1972; 202: 77-97.
  • 17 Kant JA, Lord SA, Crabtree JR. Partial mRNA sequences for human Aα,αBβ, and γ fibrinogen chains: evolutionary and functional implications. Proc Natl Acad Sci USA 1983; 80: 3953-7.
  • 18 Rixon RM, Chan WY, Davie EW, Chung DW. Characterization of a complementary deoxyribonucleic acid coding for the alpha chain of human fibrinogen. Biochemistry 1983; 21: 3237-43.
  • 19 Chung DW, Chan WY, Davie EW. Characterization of complementary deoxyribonucleic acid and genomic deoxyribonucleic acid for the beta chain of human fibrinogen. Biochemistry 1983; 21: 3244-50.
  • 20 Fowlkes DM, Mullis NT, Comeu CM, Crabtree GR. Potential basis for regulation of the coordinately expressed fibrinogen genes: Homology in the 5′ flanking regions. Proc Natl Acad Sci USA 1984; 8: 2313-7.
  • 21 Kant JA, Fornace AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985; 82: 2344-8.
  • 22 Roy S, Mukhopadhyay G, redman CM. Regulation of fibrinogen Assembly. Transfection of HepG2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265 (Suppl. 11) 6389-93.
  • 23 Roy S, Overton O, Redman C. Overexpression of any fibrinogen chain by HepG2 cells specifically elevates the expression of the other two chains. J Biol Chem 1994; 269 (Suppl. 01) 691-5.
  • 24 YU S, Sher B, Kudryk B, Redman C. Intracellular assembly of human fibrinogen. J Biol Chem 1983; 258 (Suppl. 22) 13407-10.
  • 25 Yu S, Kudryk SB, Redman CM. Fibrinogen precursors: order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-81.
  • 26 Roy SN, Procyk R, Kudryk BG, Redman CM. Assembly and secretion of recombinant human fibrinogen. J Biol Chem 1991; 266 (Suppl. 08) 4758-63.
  • 27 Hoffer MJV, Hofker MH, van Eck MM, Havekes LM, Frants LL. Evolutionary conservation of the mouse apolipoprotein E-C1-C2 gene cluster: structure and genetic variability in inbred mice. Genomics 1993; 9: 62-7.
  • 28 Hogan B, Costantini F, Lacy E. Manipulating the mouse embryo: A laboratory manual. Cold Spring Harbor Laboratory Press; New York: Cold Spring Harbor 1986
  • 29 Fort PH, Marty L, Piechaczyk M, el Sabrouty S, Dani C, Jeanteur P, Blanchard JM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 1985; 13: 1431-42.
  • 30 Koopman J, Maas A, Rezaee F, Havekes L, Verheijen J, Gijbels M, Haverkate F. Fibrinogen and atherosclerosis: A study in transgenic mice. Fibrinol Proteol 1997; 11: 19-21.
  • 31 Astrup T, Brakman P, Nissen U. The estimation of fibrinogen, a revision. Scand J Clin Lab Invest 1965; 17: 57-65.
  • 32 Rezaee F, Maas A, Verheijen JH, Koopman J. Effect of genetic background on plasma fibrinogen in mice. Possible relation with susceptibility for atherosclerosis. Atherosclerosis 2000; 151: 65.
  • 33 Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
  • 34 Huang S, Mulvihill ER, Farrel DH, Chung CW, Davie EW. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in assembly. J Biol Chem 1993; 268: 8919-26.
  • 35 Gulledge A, Lord S. Generation of a transgenic mouse model with elevated fibrinogen: Exploring a possible risk factor. Atherosclerosis 1997; 134 (1, 2) 34.
  • 36 Grieniger G, Plant PW, Chiassen MA. Selective intracellular degradation of fibrinogen and its reversal in cultured hepatocytes. J Biol Chem 1986; 259: 14973-8.
  • 37 HU CH, Harris JE, Davie EW, Chung DW. Characterization of the 5′-flanking region of the gene for thechain of human fibrinogen. J Biol Chem 1995; 270 (Suppl. 47) 28342-9.